1. Introduction {#s0005}
===============

Breast cancer (BC) is a leading cause of morbidity and mortality in women in the developed countries. Global BC incidence has been increasing by more than one million new cases every year; and is significantly higher in developed countries than in developing countries ([@bb0325], [@bb0520], [@bb0130]). The lifetime BC risk in the general population is estimated to be 10% ([@bb0595]). Several risk factors for BC have been suggested like- age of menarche and menopause, diet, reproductive history, hormone administration and genetic factors ([@bb0295], [@bb0085], [@bb0215], [@bb0270]). The etiology of breast cancer is not very well understood. However, it has been suggested that low-penetrance susceptibility genes combining with environmental factors may be important in the development of cancer ([@bb0625]). In past decade, several common low-penetrant genes have been identified as potential breast cancer susceptibility genes, one of which is 5,10-methylenetetrahydrofolate reductase (*MTHFR*) gene ([@bb0625]).

One carbon metabolism (OCM) and MTHFR enzyme play key roles in physiologic processes by regulating the one carbon units transfer between the DNA synthesis (nucleotide synthesis) and the DNA methylation cycle ([@bb0285], [@bb0140]). MTHFR reduces 10-methylenetetrahydrofolate (10-MTHF) to 5-methylenetetrahydrofolate (5-MTHF), which is a cofactor for the remethylation of homocysteine to convert it to S-adenosyl methionine (SAM). SAM is sole methyl group donor for DNA, RNA and protein methylation. Dysfunction of the OCM cycle has been linked to congenital abnormalities ([@bb0445], [@bb0620], [@bb0425]), psychiatric disorders ([@bb9010], [@bb9000]), and different types of cancers ([@bb0440], [@bb0630], [@bb0275]).

C677T is the most common and functional polymorphism in the *MTHFR* gene, which involves a cytosine-to-thymine substitution at position 677, a consequence of transformation from an alanine to a valine in the enzyme (Ala222Val) ([@bb0145]). This change leads to reduced enzyme activity, and individuals heterozygous (677CT) or homozygous (677TT) for this variant had enzyme activity reduced to approximately 60% and 30%, respectively, of that of the wild type (677CC) ([@bb0535]) and elevate homocysteine levels ([@bb0190], [@bb0265]). The genotype frequencies of the polymorphism are CC, 0.583; CT, 0.35; TT, 0.067 in Europeans and CC, 0.267; CT, 0.444; TT, 0.289 in Asians ([www.hapmap.org](http://www.hapmap.org){#ir0005}).

MTHFR gene T allele has been widely studied as a possible low-penetrance susceptibility allele for a variety of cancers, and in particular, BC. Several studies reported significant association between C677T polymorphism and BC risk ([@bb0245], [@bb0360], [@bb0170], [@bb0555], [@bb0075]), however some other studies have reported no association between BC and C677T polymorphism ([@bb0500], [@bb0205], [@bb0570], [@bb0365], [@bb0370]). The variation of these results might be induced by difference in ethnicities, sample size, study design and background of patients as well as random error ([@bb0560]). Hence we performed a meta-analysis of published case control studies to reevaluate the association between C677T polymorphism and BC susceptibility. Meta-analysis is a technique that has proven useful in resolving discrepancies between association studies is meta-analysis ([@bb0480], [@bb0350]). Meta-analysis is a quantitative method of combining the results independent studies and synthesizing summaries and conclusions. This method increases power to distinguish between small effects and no effect.

2. Methods {#s0010}
==========

2.1. Literature search and inclusion/exclusion criteria {#s0015}
-------------------------------------------------------

The articles were retrieved by searching the PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), Google Scholar (<http://scholar.google.com>), and Springer Link (<http://link.springer.com>) databases using the keywords "breast cancer", "C677T", "methylenetetrahydrofolate reductase" and "MTHFR" published up to March 31, 2015. In addition references of reviews and meta-analyses were examined to identify potential additional studies.

The inclusion criteria for the present meta-analysis were: (a) studies should investigated associations between *MTHFR* C677T polymorphism and BC; (b) studies should provide complete data on genotype number and frequencies of cases and controls for calculation of odd ratios (ORs) with 95% confidence intervals (CIs); (c) studies should be case--control studies. Exclusion criteria were as follows: (a) study design other than case--control (e.g., case reports, cohort study design without control group); (b) main outcome other than the risk of BC among genotypes (e.g., pharmacogenetic studies); and (c) reports were further excluded if they evaluated the role of *MTHFR* variants in other cancers. For duplicate publications, study with small sample size was excluded.

2.2. Extraction of data {#s0020}
-----------------------

The characteristics of the included studies were independently extracted by two investigators (UY and VR) through a standardized protocol. They independently extracted the following data from each publication: author name; country of origin; selection and characteristics of cases and controls; source of control, demographic information; racial descent of the study population; numbers of eligible and genotyped cases and controls; and numbers of cases and controls for each *MTHFR* genotype. Number and frequency of genotypes and alleles in both case and control groups were extracted or calculated from published data to re-calculate crude ORs and their 95% confidence intervals (95% CIs). Results were compared and minor disagreements were resolved by discussion. If essential information was missing from the article, the authors of the respective papers were contacted and asked to provide additional data.

2.3. Statistical analysis {#s0025}
-------------------------

The strength of association between the *MTHFR* C677T polymorphism and BC was estimated using odds ratios (OR), with the corresponding 95% confidence intervals (95% CI). We estimated the risk of C677T polymorphism using all genetic models viz. allele contrast/additive model (T vs. C), homozygote model (TT vs. CC), co-dominant/heterozygote model (CT vs. CC), dominant model (TT + CT vs. CC) and recessive model (TT vs. CT + CC). We tested heterogeneity between studies using Cochran\'s chi-square-based Q-statistic and estimated the degree of heterogeneity with I^2^. I^2^ ranges from 0% to 100 ([@bb0210], [@bb0185]). When low heterogeneity (I^2^ \< 50%) was observed, then overall OR was estimated under the fixed-effects model ([@bb0380]), otherwise (I^2^°≥°50%) under the random-effects model ([@bb0095]).

Two methods were used to detect possible publication bias in meta-analysis: graphical and statistical. The funnel plot is a commonly used graphical test and Egger\'s ([@bb0115]) and Begg and Mazumdar ([@bb0030]) are statistical methods. Pearson\'s x^2^ test was used to determine whether genotype of control population were in Hardy--Weinberg equilibrium (HWE) or not (P \> 0.05). Sensitivity analyses were performed by excluding studies with a small number of cases (n \< 100) and studies with control population violating HWE. Subgroup analyses based on ethnicity were also performed to investigate the cause of heterogeneity.

Meta-analysis was performed using Open Meta Analyst ([@bb0545]) and publication bias analysis was performed using Mix version 1.7 ([@bb0025]). All P values are two-tailed with a significance level at 0.05.

2.4. Quality score assessment {#s0030}
-----------------------------

Method of [@bb0165] was adopted for quality score assessment. The quality scores ranged from 0 to 10 and studies with score \< 5 was defined as low quality, and studies with score ≥ 7 was defined as high quality.

3. Results {#s0035}
==========

3.1. Characteristics of included studies {#s0040}
----------------------------------------

A flow chart summarizing the process of study selection is shown in [Fig. 1](#f0005){ref-type="fig"}. Initially, the highly sensitive search strategy of Pubmed, Google Scholar, and Springer Link databases, 192 articles were retrieved. After screening the titles and abstracts of all retrieved articles, 119 articles were excluded. Then full texts were reviewed and 2 articles (only cases) were further excluded. Based on the inclusion and exclusion criteria, finally, seventy one studies were included in the present met-analysis ([@bb0245], [@bb0330], [@bb0355], [@bb0360], [@bb0500], [@bb0170], [@bb0205], [@bb0230], [@bb0550], [@bb0555], [@bb0345], [@bb0410], [@bb0005], [@bb0015], [@bb0100], [@bb0225], [@bb0290], [@bb0570], [@bb0020], [@bb0065], [@bb0195], [@bb0200], [@bb0405], [@bb0420], [@bb0010], [@bb0035], [@bb0470], [@bb0540], [@bb0575], [@bb0055], [@bb0125], [@bb0150], [@bb0180], [@bb0235], [@bb0315], [@bb0365], [@bb0370], [@bb0385], [@bb0415], [@bb0610], [@bb0075], [@bb0220], [@bb0280], [@bb0300], [@bb0395], [@bb0525], [@bb0175], [@bb0260], [@bb0340], [@bb0375], [@bb0450], [@bb0515], [@bb0580], [@bb0605], [@bb0080], [@bb0255], [@bb0070], [@bb0090], [@bb0240], [@bb0250], [@bb0135], [@bb0160], [@bb0310], [@bb0305], [@bb0335], [@bb0435], [@bb0495], [@bb0120], [@bb0295], [@bb0475], [@bb0060], [@bb0490]). One author (e[@bb0305]) investigated fiv different population. We included each population as separate article so total seventy five article were included in the present meta-analysis ([Table 1](#t0005){ref-type="table"}).

In seventy five studies included in the present meta-analysis, the smallest case sample size was 32 ([@bb0570]) and highest sample size was 4778 ([@bb0225]). In included studies, total cases were 31,315 with CC (13,960), CT (13,328) and TT (4027), and controls were 35,608 with CC (16,527), CT (14,868), and TT (4213). In controls genotype percentage of CC, CT and TT were 46.41%, 41.75% and 11.83% respectively. In cases genotype percentage of CC, CT and TT were 44.58%, 42.56% and 12.86% respectively. Frequencies of CC genotype and C allele were highest in both cases and controls.

Out of 75 studies, only twenty studies reported OR above one and significant association between C677T polymorphism and BC ([@bb0355], [@bb0360], [@bb0170], [@bb0230], [@bb0555], [@bb0345], [@bb0410], [@bb0290], [@bb0405], [@bb0575], [@bb0150], [@bb0385], [@bb0315], [@bb0610], [@bb0580], [@bb0070], [@bb0090], [@bb0435]). Control population of eleven studies ([@bb0355], [@bb0170], [@bb0230], [@bb0550], [@bb0555], [@bb0570], [@bb0195], [@bb0200], [@bb0340], [@bb0515]) was not in Hardy--Weinberg equilibrium ([Table 1](#t0005){ref-type="table"}).

3.2. Meta-analysis {#s0045}
------------------

The meta-analysis was carried out using all five genetic models- allele contrast (T vs. C), co-dominant (CT vs. CC), homozygote (TT vs. CC), dominant (TT + CT vs. CC), and recessive (TT vs. CT + CC) models. Meta-analysis with allele contrast (T vs. C) showed moderate significant association with both fixed effect (OR = 1.05; 95%CI = 1.02--1.07; p = \< 0.001) and random effect model (OR = 1.08; 95% CI = 1.03--1.13; p = \< 0.001). Subjects with T allele showed a slightly increased risk of BC ([Table 2](#t0010){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}).

An increased significant association was found between BC and mutant genotype (TTvs.CC; homozygote model) with both fixed (OR = 1.10; 95%CI = 1.04--1.16; p = \< 0.001) and random (OR = 1.17; 95%CI = 1.06--1.28; p = 0.001) effect models ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}). Association of mutant heterozygous genotype (CT vs.CC; co-dominant model) was observed significant with BC using fixed (OR = 1.05; 95%CI = 1.01--1.08; p = 0.005) and random (OR = 1.05; 95%CI = 1.01--1.10; p = 0.01) effect models ([Table 2](#t0010){ref-type="table"}). Combined mutant genotypes (TT + CT vs. CC; dominant model) showed positive association with BC using both fixed (OR = 1.06; 95%CI = 1.02--1.09; p = \< 0.001) and random (OR°=°1.08; 95%CI = 1.03--1.14; p = \< 0.001) effect models. Similarly the recessive genotypes model (TT vs. CT + CC) also showed positive association fixed (OR = 1.07; 95%CI = 1.02--1.13; p = 0.002) and random (OR°=°1.12; 95%CI = 1.03--1.22; p = 0.005) effect models ([Table 2](#t0010){ref-type="table"}). In allele contrast cumulative meta-analysis, after addition of [@bb0035] study, the pooled turned statistically significant and remained significant after addition of subsequent studies (details not given).

A true heterogeneity existed between studies for allele contrast (P~heterogeneity~ = \< 0.001, Q = 203.99, I^2^ = 63%, t^2^ = 0.019, z = 3.73), homozygote (P~heterogeneity~ = \< 0.001, Q = 186.33, I^2^ = 60%, t^2^ = 0.079, z = 3.24), dominant (P~heterogeneity~ = \< 0.001, Q = 147.7, I^2^ = 48%, t^2^ = 0.019, z = 3.29) and recessive (P~heterogeneity~ = \< 0.001, Q = 163.7, I^2^ = 55%, t^2^ = 0.054, z = 2.83) comparisons.

3.3. Sensitivity analysis {#s0050}
-------------------------

Sensitivity analysis was performed by eliminating studies with small sample size (\< 100) and control population deviating from HWE. Control population of eleven studies was not in HWE ([@bb0355], [@bb0170], [@bb0205], [@bb0230], [@bb0555], [@bb0570], [@bb0195], [@bb0200], [@bb0260], [@bb0340], [@bb0515]) and heterogeneity was decreased after exclusion of these studies (I^2^ = 52%; p = \< 0.001). Sample size of seventeen studies was less than 100 ([@bb0410], [@bb0100], [@bb0570], [@bb0020], [@bb0200], [@bb0575], [@bb0235], [@bb0315], [@bb0610], [@bb0395], [@bb0175], [@bb0375], [@bb0450], [@bb0255], [@bb0250], [@bb0305], [@bb0490]) and after exclusion of these studies heterogeneity was slightly decreased (I^2^ = 61%; p = 0.002).

3.4. Subgroup analysis {#s0055}
----------------------

Out of 75 studies included in the present meta-analysis, 37 studies were carried out on Asian population, and 31 studies were carried out on Caucasian population and other studies were carried on other ethnic group and we grouped those studies in mixed population subgroup (7 studies). The subgroup analysis by ethnicity revealed significant association between *MTHFR* C677T polymorphism and BC in Asian population (T vs. C: OR = 1.11; 95% CI = 1.02--1.21; p = 0.01; I^2^ = 75%; P~heterogeneity~ = \< 0.001; CT vs. CC: OR = 1.04; 95% CI = 0.99--1.10; p = 0.08; I^2^ = 43%; P~heterogeneity~ = 0.003; TT vs. CC: OR = 1.26; 95% CI = 1.06--1.51; p = 0.009; I^2^ = 71%; P~heterogeneity~ = \< 0.001; TT + CT vs. CC: OR = 1.10; 95% CI = 1.00--1.20; p = 0.04; I^2^ = 64; P~heterogeneity~ = \< 0.001; TT vs. CT + CC: OR = 1.21; 95% CI = 1.04--1.40; p = 0.01; I^2^ = 65%; P~heterogeneity~ = \< 0.001) ([Table 2](#t0010){ref-type="table"}). In Caucasian subgroup analysis, heterogeneity was low and except allele contrast model, significant association was not found between C677T polymorphism and BC risk (T vs. C: OR = 1.03; 95% CI = 1.00--1.06; p = 0.02; I^2^ = 32%; P~heterogeneity~ = 0.04; CT vs. CC: OR = 1.03; 95% CI = 0.99--1.12; p = 0.09; I^2^ = 0%; P~heterogeneity~ = 0.79; TT vs. CC: OR = 1.06; 95% CI = 0.99--1.14; p = 0.05; I^2^ = 43%; P~heterogeneity~ = 0.007; TT + CT vs. CC: OR = 1.04; 95% CI = 1.00--1.08; p = 0.05; I^2^ = 0; P~heterogeneity~ = 0.56; TT vs. CT + CC: OR = 1.05; 95% CI = 0.99--1.12; p = 0.09; I^2^ = 47%; P~heterogeneity~ = 0.002). In mixed subgroup analysis, significant association was found in allele contrast, co-dominant and dominant models (T vs. C: OR = 1.10; 95% CI = 0.99--1.21; p = 0.05; I^2^ = 41%; P~heterogeneity~ = 0.11; CT vs. CC: OR = 1.24; 95% CI = 1.0--1.55; p = 0.04; I^2^ = 55%; P~heterogeneity~ = 0.03; TT vs. CC: OR = 1.14; 95% CI = 0.91--1.42; p = 0.23; I^2^ = 2%; P~heterogeneity~ = 0.40; TT + CT vs. CC: OR = 1.23; 95% CI = 0.99--1.53; p = 0.05; I^2^ = 57%; P~heterogeneity~ = 0.03; TT vs. CT + CC: OR = 1.03; 95% CI = 0.84--1.26; p = 0.74; I^2^ = 0%; P~heterogeneity~ = 0.77) ([Table 2](#t0010){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}).

Sub-group analysis based on menstrual status i.e. premenopausal and postmenopausal was performed. Out of 75 included studies, in 9 studies BC cases was from premenopausal group and in other 9 studies BC cases was from postmenopausal group. In remaining 57 studies menstrual status was not mentioned. In both the group, pre and post-menopausal groups no significant association was observed using all five genetic models.

Sub-group analysis based on source of control population i.e. hospital based or population based was also performed. Out of 75 included studies, control population in 34 studies was hospital based and in 32 studies control population was from population and in 9 studies source of controls was not mentioned. In hospital based control group studies, (number of studies = 34; 12,515/13,560 cases/controls), allele contrast meta-analysis showed significant association (OR~TvsC~ = 1.14; 95%CI = 1.05--1.23; p \< 0.001). In population based control group studies, (number of studies = 32; 2916/4300 cases/controls), allele contrast meta-analysis did not show significant association (OR~TvsC~ = 1.03; 95%CI = 0.98--1.09; p = 0.15).

3.5. Publication bias {#s0060}
---------------------

Funnel plots and Egger\'s test were performed to estimate the risk of publication bias. Except allele contrast and homozygote model, publication bias was absent (T vs. C: P~Begg\'s\ test~ = 0.03, P~Egger\'s\ test~ = 0.03; CT vs. CC: P~Begg\'s\ test~ = 0.41, P~Egger\'s\ test~ = 0.29; TT vs. CC: P~Begg\'s\ test~ = 0.10, P~Egger\'s\ test~ = 0.03; Dominant model TT + CT vs. CC:, P~Begg\'s\ test~ = 0.27, P~Egger\'s\ test~ = 0.06; Recessive model TT vs. CT + CC: P~Begg\'s\ test~ = 0.18, P~Egger\'s\ test~ = 0.05) ([Fig. 4](#f0020){ref-type="fig"}).

4. Discussion {#s0065}
=============

Present meta-analysis investigated association of the *MTHFR* C677T polymorphism with BC risk (31,315 patients and 35,608 controls from 75 case--control studies). Results of meta-analysis suggested moderate significant genetic association between the *MTHFR* C677T polymorphism and BC. This result is in line with that of eight other previously published meta-analyses that had included fewer case control studies of the *MTHFR* C677T polymorphism and BC ([@bb0320], [@bb0325], [@bb0440], [@bb0600], [@bb0430], [@bb0625], [@bb0375], [@bb0635]). This is the largest meta-analysis carried out so far to investigate the association between *MTHFR* and BC.

In subgroup analysis based of ethnicity, we find significant association between C677T polymorphism and BC risk in Asian population but did not find such association in Caucasian population. These discrepancies in the results could be arise because of the multitude of the factors such as the differences in the allele frequencies due to ethnic variations, nutritional status especially folate intake and sample size studied etc. Frequency of *MTHFR* C677T polymorphism varies in different ethnic populations. Recently, [@bb0585] reported that T allele and TT genotype frequencies in Asian population (37.2% and 16.9%) are higher in comparison to Caucasian populations (33.6% of T allele and 12.1% of TT genotype).

MTHFR enzyme function may influence cancer risk in two ways. The substrate of MTHFR enzyme, 5,10- methylenetetrahydrofolate, is involved in the conversion of deoxyuridylate monophosphate to deoxythymidylate monophosphate, and low levels of 5,10-methylenetetrahydrofolate would lead to an increased deoxyuridylate monophosphate/deoxythymidylate monophosphate ratio. In this situation, increased incorporation of uracil into DNA in place of thymine may follow, resulting in an increased chance of point mutations and DNA/chromosome breakage ([@bb0505], [@bb0050], [@bb0040]). The second way by which dysfunctional MTHFR increases risk of cancer is determined by the level of SAM, which is necessary for maintenance of the methylation patterns in DNA. Altered methylation pattern may modify DNA conformation and gene expression. A less active form of MTHFR leads to lower SAM levels and consequently to hypomethylation and increase the risk of cancers ([@bb0050], [@bb0510], [@bb0110]).

The role of folate in breast cancer has been investigated in several dietary studies and most have shown folate consumption to be inversely related to breast cancer risk ([@bb0615], [@bb0460], [@bb0155], [@bb0580]) and adequate folate intake has been associated with a substantially decreased risk of cancer. Cancer risk modification conferred by C677T polymorphism is further modified by the status of folate and nutrients involved in one-carbon and folate metabolism ([@bb0535], [@bb0455], [@bb0485]). We did not done sub group analysis on the basis of folate concentrations. In total 75 included studies, folate intake information was reported only in 12 studies, out of which few authors reported folate uptake dose and others reported blood level of folate. With increased folic acid fortification in the Caucasian population, the general intake of folate may be higher than that from the Asian population, whose folate intake is primarily obtained from unfortified diets. Further, in Asian population malnutrition, low folate intake and impaired folate absorption due to infectious diseases were already reported ([@bb0465], [@bb0565]). Folate supplementation would outweigh the negative effects of C677T polymorphism. Hence the effect of *MTHFR* on breast cancer risk in a particular population may depend on the intake level of folate food in that population.

Meta-analysis is a powerful tool for analyzing cumulative data of studies where the individual sample sizes are small and the statistical power low ([@bb0590], [@bb0445]). Several meta-analyses were published to assess the role of *MTHFR* polymorphism in cancer development like: lung cancer ([@bb0045]), pancreatic cancer ([@bb0530]), prostate cancer ([@bb0630]), esophageal cancer ([@bb0560]), ovarian cancer ([@bb0105]) and cervical cancer ([@bb0390]).

We identified ten meta-analyses ([@bb0500], [@bb0325], [@bb0320], [@bb0440], [@bb0600], [@bb0325]; [@bb0625], [@bb0340], [@bb0375], [@bb0635]) identified concerning similar topic as we did during the literature search. A comparative details of all the meta-analysis published so far (including present) were presented in [Table 3](#t0015){ref-type="table"}. [@bb0635] carried out first meta-analysis of *MTHFR* C677T genotype of 18 studies and reported significant heterogeneity (p = 0.08, I^2^ = 34%) and non-significant association (OR = 1.02; 95% confidence interval (0.95--1.10) in allele contrast model. [@bb0340] carried out meta-analysis of 22 studies and showed no association between TT (mutant homozygote) vs. CC genotypes and breast cancer risk (OR = 0.99; 95% CI = 0.86--1.15), based on 8330 cases and 10,825 controls. [@bb0375] performed a meta-analysis of 18 studies examining the association between polymorphisms C677T and BC risk and found positive association between the TT genotype BC risk. A meta-analysis of 41 retrospective studies (16,480 cases and 22,388 controls) was carried out by [@bb0325] and reported significant elevated breast cancer risk using all five genetic model (TT vs. CC: OR = 1.13, 95% CI = 1.01--1.25). [@bb0625] reported significant association between 677T polymorphism with BC (TT vs. CC: OR = 1.11, 95% CI = 1.01--1.23 and suggested *MTHFR* T allele as a low-penetrant risk factor for developing breast cancer. [@bb0600] carried out meta-analysis of 51 studies including 20,907 cases and 23,905 controls and reported significant associations between *MTHFR* C677T polymorphism and BC risk. [@bb0325], [@bb0320], [@bb0440] and [@bb0500] conducted meta-analyses on 37 studies (15,260 cases and 20,411 controls), 57 studies (25,877 breast cancer cases and 29,781 controls), 36 studies (8040 cases and 10,008 controls) and 41 studies (16,480 cases and 22,388 controls), and 61 studies (28,031 Cases and 31,880 Controls), respectively, and except [@bb0500], all were reported significant association between C677T polymorphism and BC risk. Compared with present meta-analysis, most of these meta-analyses included less number of studies and smaller total sample was analyzed.

Presence of higher heterogeneity showed that there were significant differences between individual studies. Hence, sensitivity and subgroup analyses were performed to explore the causes of heterogeneity. Sensitivity analysis showed that even after excluding studies with a small number of cases (n \< 100), or having controls violating the HWE, the heterogeneity decreased slightly. However, the larger sample size does not mean the study is without limitations. The current meta-analysis has few limitations also like - (i) only published studies were included, thus possibility of publication bias cannot be excluded, (ii) single gene polymorphism of folate metabolic pathway was considered, and (iii) finally, due to lack of data, gene--gene and gene--environment interactions could not be included.

We hope that this meta-analysis of the most comprehensive literature addressing the association is yielded convincing evidence to determine the role of *MTHFR* C677T polymorphism in BC risk. In summary, results of present meta-analysis showed modest association between MTHFR C677T polymorphism with breast cancer in total studies. However, sub-group analysis results based on ethnicity showed strong significant association between TT genotype and breast cancer (TT vs. CC; OR°=°1.26; 95% CI: 1.06--1.51; p = 0.009) in Asian population but in Caucasian population such association was not observed (TT vs. CC; OR°=°1.08; 95% CI: 0.99--1.14; p = 0.05). However, presence of publication bias and higher between study heterogeneity suggested that results should be interpreted cautiously and also indicated that the observed association may differ in strength between populations, or may not exist at all in some populations.
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###### 

Characteristics of the eligible studies considered in the meta-analysis.

  Study ID    Country            Ethnicity   Case/control   Control source                        Genotyping method                     HWE         Study quality
  ----------- ------------------ ----------- -------------- ------------------------------------- ------------------------------------- ----------- ---------------
  [@bb0490]   UK                 Caucasian   54/57          PB                                    PCR-RFLP                              0.10        4
  [@bb0060]   Australia          Caucasian   335/233        HB                                    PCR-RFLP                              0.41        6.5
  [@bb0475]   USA                Caucasian   105/247        HB                                    PCR-RFLP                              0.64        6
  [@bb0300]   Austria            Caucasian   494/495        PB                                    PCR-RFLP                              0.33        7
  [@bb0120]   Turkey             Caucasian   118/193        HB                                    PCR-RFLP                              0.16        6.5
  [@bb0465]   China              Asian       1112/1160      PB                                    PCR-RFLP                              0.44        8.5
  [@bb0135]   Poland             Caucasian   223/298        NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.68        7
  [@bb0310]   Australia          Caucasian   186/147        HB                                    PCR-RFLP                              0.07        7.5
  [@bb0160]   Korea              Asian       334/551        PB                                    PCR-RFLP                              0.10        7
  [@bb0335]   Taiwan             Asian       88/342         PB                                    PCR-RFLP                              0.38        7
  [@bb0305]   Hawaiian           Caucasian   1189/2414      PB                                    TaqMan                                0.75        8.5
  [@bb0435]   China              Asian       217/218        PB                                    PCR-RFLP                              0.59        4.5
  [@bb0070]   USA                Caucasian   1063/1104      PB                                    PCR-RFLP                              0.68        9.5
  [@bb0250]   Greece             Caucasian   42/51          NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.31        5
  [@bb0090]   Turkey             Caucasian   189/223        NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.75        7
  [@bb0240]   Germany            Caucasian   557/633        PB                                    MALDI-TOF                             0.19        8
  [@bb0080]   China              Asian       142/285        HB                                    PCR-RFLP                              0.47        7
  [@bb0255]   India              Asian       88/95          HB                                    PCR-RFLP                              0.69        6.5
  [@bb0580]   USA                Caucasian   1063/1104      PB                                    PCR-RFLP                              0.68        8.5
  [@bb0175]   Turkey             Caucasian   40/68          NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.87        6
  [@bb0260]   China              Asian       125/103        PB                                    PCR-RFLP                              0.04        7
  [@bb0340]   Poland             Caucasian   1974/2282      PB                                    TaqMan                                0.01        8
  [@bb0375]   Italy              Caucasian   46/80          PB                                    TaqMan                                0.51        4
  [@bb0450]   Croatia            Caucasian   93/65          PB                                    PCR-RFLP                              0.11        6
  [@bb0515]   USA                Others      494/494        PB                                    TaqMan                                0.01        7
  [@bb0605]   Taiwan             Asian       119/420        PB                                    PCR-RFLP                              0.33        7.5
  [@bb0220]   Singapore          Asian       380/662        PB                                    TaqMan                                0.17        9
  [@bb0280]   Canada             Caucasian   944/680        HB                                    Mass-array system                     0.08        7.5
  [@bb0525]   Japan              Asian       454/909        HB                                    TaqMan                                0.52        9.5
  [@bb0075]   Taiwan             Asian       349/530        HB                                    PCR-RFLP                              0.62        6.5
  [@bb0300]   Austria            Caucasian   105/105        NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.68        6
  [@bb0395]   India              Asian       35/33          HB                                    PCR-RFLP                              0.95        4
  [@bb0125]   Sweden             Caucasian   540/1074       PB                                    MALDI-TOF                             0.70        6
  [@bb0150]   China              Asian       624/624        PB                                    PCR-RFLP                              0.59        9
  [@bb0365]   Japan              Asian       388/387        HB                                    TaqMan                                0.66        6.5
  [@bb0415]   USA                Caucasian   994/1802       PB                                    TaqMan                                0.39        9
  [@bb0180]   Spain              Caucasian   135/292        PB                                    PCR-RFLP                              0.82        7
  [@bb0055]   Turkey             Caucasian   110/95         NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.39        4.5
  [@bb0385]   USA                Caucasian   318/647        PB                                    ASPE                                  0.67        8.5
  [@bb0365]   Brazil             Others      458/458        HB                                    NR[⁎](#tf0005){ref-type="table-fn"}   0.30        8.5
  [@bb0315]   China              Asian       65/143         PB                                    PCR-RFLP                              0.18        7
  [@bb0610]   China              Asian       80/80          HB                                    PCR-RFLP                              0.51        6.5
  [@bb0235]   China              Asian       41/100         NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.74        7.5
  [@bb0035]   USA                Caucasian   939/1163       HB                                    PCR-RFLP                              0.05        8
  [@bb0010]   Arab               Asian       100/100        HB                                    TaqMan                                0.80        6.5
  [@bb0470]   Indian             Asian       563/487        HB                                    TaqMan                                0.42        9
  [@bb0540]   Russia             Asian       837/778        PB                                    PCR-RFLP                              0.80        8
  [@bb0575]   China              Asian       80/80          HB                                    PCR-RFLP                              0.51        5.5
  [@bb0020]   Brazil             Others      68/85          PB                                    PCR-RFLP                              0.59        4.5
  [@bb0065]   Caucasian          Caucasian   522/269        PB                                    Sequencing                            0.88        6
  [@bb0195]   Iran               Asian       294/300        HB                                    PCR-RFLP                              \< 0.0001   3
  [@bb0200]   China              Asian       95/90          PB                                    PCR-RFLP                              0.02        6.5
  [@bb0405]   India              Asian       244/244        HB                                    PCR-RFLP                              0.17        7
  [@bb0420]   India              Asian       130/125        PB                                    PCR-RFLP                              0.06        6
  [@bb0005]   Pakistan           Asian       110/110        HB                                    PCR-RFLP                              0.85        5
  [@bb0015]   Mixed, Caucasian   Caucasian   176/176        HB                                    PCR-RFLP                              0.38        5.5
  [@bb0100]   Morocco            Others      96/117         HB                                    PCR-RFLP                              0.78        7
  [@bb0225]   Mixed, Caucasian   Caucasian   4778/3350      PB                                    TaqMan                                0.15        7
  [@bb0290]   Syria              Asian       119/126        HB                                    PCR-RFLP                              0.35        6.5
  [@bb0570]   China              Asian       32/37          NR[⁎](#tf0005){ref-type="table-fn"}   PCR-RFLP                              0.03        6
  [@bb0345]   China              Asian       435/435        HB                                    PCR-RFLP                              0.57        6
  [@bb0410]   Turkey             Caucasian   51/106         NR[⁎](#tf0005){ref-type="table-fn"}   Strip-assay                           0.08        4
  [@bb0170]   China              Asian       310/381        HB                                    Sequenom                              \< 0.0001   6
  [@bb0205]   Taiwan             Asian       1232/1232      HB                                    PCR-RFLP                              0.01        8
  [@bb0230]   China              Asian       535/673        HB                                    PCR-RFLP                              \< 0.0001   7
  [@bb0550]   China              Asian       435/435        HB                                    Sequenom                              0.22        6
  [@bb0555]   China              Asian       297/306        HB                                    Sequenom                              0.00        8
  [@bb0245]   Cyprus             Caucasian   1065/1157      PB                                    TaqMan                                0.09        9.5
  [@bb0355]   Ecuador            Others      114/195        HB                                    PCR-RFLP                              0.00        7
  [@bb0360]   China              Asian       560/560        HB                                    TaqMan                                0.27        9
  [@bb0500]   India              Asian       588/508        HB                                    PCR-RFLP                              0.37        5.5

NR = not reported.

###### 

Summary estimates for the odds ratio (OR) of MTHFR C677T in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I^2^ metric: overall analysis, and subgroup analyses.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               Genetic contrast              Fixed effect\                 Random effect\                Heterogeneity p-value (Q test)   I^2^ (%)
                                                             OR (95% CI), p                OR (95% CI), p                                                 
  ---------------------------- ----------------------------- ----------------------------- ----------------------------- -------------------------------- ----------
  All\                         Allele contrast (T vs. C)     1.05 (1.02--1.07), \< 0.001   1.08 (1.03--1.13), \< 0.001   \< 0.001                         63
  (75 studies)                                                                                                                                            

  Dominant (TT + CT vs. CC)    1.06 (1.02--1.09), \< 0.001   1.08 (1.03--1.14), 0.002      \< 0.001                      48                               

  Homozygote (TT vs. CC)       1.10 (1.04--1.16), \< 0.001   1.17 (1.06--1.28), 0.001      \< 0.001                      60                               

  Co-dominant (CT vs. CC)      1.05 (1.01--1.08), 0.005      1.05 (1.01--1.10), 0.01       0.01                          29                               

  Recessive (CC + CT vs. TT)   1.07 (1.02--1.13), 0.002      1.12 (1.03--1.22), 0.005      \< 0.001                      55                               

                                                                                                                                                          

  Ethnicity                                                                                                                                               

  Asian\                       Allele contrast (T vs. C)     1.06 (1.02--1.11), \< 0.001   1.11 (1.02--1.21), 0.01       \< 0.001                         75
  (37 studies)                                                                                                                                            

  Dominant (TT + CT vs. CC)    1.07 (1.01--1.12), 0.009      1.10 (1.00--1.20), 0.04       \< 0.001                      64                               

  Homozygote (TT vs. CC)       1.15 (1.06--1.25), \< 0.001   1.26 (1.06--1.51), 0.009      \< 0.001                      71                               

  Co-dominant (CT vs. CC)      1.04 (0.99--1.10), 0.08       1.05 (0.97--1.14), 0.19       0.003                         43                               

  Recessive (CC + CT vs. TT)   1.12 (1.04--1.21), 0.003      1.21 (1.04--1.40), 0.01       \< 0.001                      65                               

  Caucasian\                   Allele contrast (T vs. C)     1.03 (1.00--1.06), 0.02       1.04 (1.00--1.09), 0.04       0.04                             32
  (31 studies)                                                                                                                                            

  Dominant (TT + CT vs. CC)    1.04 (1.00--1.08), 0.05       1.04 (1.00--1.08), 0.05       0.56                          0                                

  Homozygote (TT vs. CC)       1.06 (0.99--1.14), 0.05       1.08 (0.97--1.21), 0.12       0.007                         43                               

  Co-dominant (CT vs. CC)      1.03 (0.99--1.08), 0.12       1.03 (0.99--1.08), 0.12       0.79                          0                                

  Recessive (CC + CT vs. TT)   1.05 (0.99--1.12), 0.09       1.07 (0.96--1.19), 0.18       0.002                         47                               

  Others\                      Allele contrast (T vs. C)     1.10 (0.99--1.21), 0.05       1.12 (0.97--1.28), 0.09       0.11                             41
  (7 studies)                                                                                                                                             

  Dominant (TT + CT vs. CC)    1.17 (1.02--1.33), 0.01       1.23 (0.99--1.53), 0.05       0.03                          57                               

  Homozygote (TT vs. CC)       1.14 (0.91--1.42), 0.23       1.14 (0.91--1.44), 0.22       0.40                          2                                

  Co-dominant (CT vs. CC)      1.19 (1.03--1.36), 0.01       1.24 (1.00--1.55), 0.04       0.03                          55                               

  Recessive (CC + CT vs. TT)   1.03 (0.84--1.26), 0.74       1.03 (0.84--1.27), 0.73       0.77                          0                                

                                                                                                                                                          

  Study design                                                                                                                                            

  Hospital based\              Allele contrast (T vs. C)     1.07 (1.03--1.12), \< 0.001   1.14 (1.05--1.23), \< 0.001   \< 0.001                         73
  (34 studies)                                                                                                                                            

  Dominant (TT + CT vs. CC)    1.08 (1.03--1.14), 0.001      1.14 (1.04--1.26), 0.004      \< 0.001                      65                               

  Homozygote (TT vs. CC)       1.15 (1.06--1.25), \< 0.001   1.27 (1.08--1.50), 0.003      \< 0.001                      69                               

  Co-dominant (CT vs. CC)      1.06 (1.01--1.12), 0.02       1.10 (1.01--1.20), 0.02       \< 0.001                      54                               

  Recessive (CC + CT vs. TT)   1.12 (1.04--1.21), 0.002      1.20 (1.05--1.39), 0.008      \< 0.001                      63                               

  Population based\            Allele contrast (T vs. C)     1.03 (1.00--1.06), 0.04       1.03 (0.98--1.09), 0.15       0.001                            48
  (32 studies)                                                                                                                                            

  Dominant (TT + CT vs. CC)    1.04 (0.99--1.08), 0.05       1.04 (0.98--1.09), 0.12       0.13                          22                               

  Homozygote (TT vs. CC)       1.06 (0.99--1.13), 0.07       1.08 (0.96--1.21), 0.16       \< 0.001                      50                               

  Co-dominant (CT vs. CC)      1.03 (0.99--1.08), 0.10       1.03 (0.99--1.08), 0.10       0.61                          0                                

  Recessive (CC + CT vs. TT)   1.04 (0.97--1.10), 0.20       1.05 (0.95--1.16), 0.27       0.003                         45                               

                                                                                                                                                          

  Menopausal status                                                                                                                                       

  Pre-menopausal\              Allele contrast (T vs. C)     1.01 (0.90--1.12), 0.84       1.01 (0.98--1.12), 0.84       0.68                             0
  (9 studies)                                                                                                                                             

  Dominant (TT + CT vs. CC)    1.00 (0.87--1.17), 0.90       1.00 (0.86--1.16), 0.92       0.45                          0                                

  Homozygote (TT vs. CC)       1.01 (0.80--1.28), 0.89       1.01 (0.80--1.28), 0.89       0.63                          0                                

  Co-dominant (CT vs. CC)      1.00 (0.85--1.17), 0.99       1.01 (0.84--1.21), 0.88       0.25                          20                               

  Recessive (CC + CT vs. TT)   1.02 (0.82--1.27), 0.83       1.02 (0.81--1.27), 0.84       0.50                          0                                

  Post-menopausal\             Allele contrast (T vs. C)     1.03 (0.95--1.12), 0.40       1.05 (0.92--1.20), 0.39       0.03                             51
  (9 studies)                                                                                                                                             

  Dominant (TT + CT vs. CC)    1.08 (0.96--1.20), 0.16       1.09 (0.95--1.25), 0.20       0.22                          24                               

  Homozygote (TT vs. CC)       1.01 (0.85--1.20), 0.87       1.06 (0.77--1.45), 0.71       0.01                          57                               

  Co-dominant (CT vs. CC)      1.10 (0.98--1.23), 0.10       1.10 (0.98--1.23), 0.10       0.62                          0                                

  Recessive (CC + CT vs. TT)   0.96 (0.82--1.13), 0.68       0.99 (0.75--1.30), 0.96       0.04                          48                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

A comparative analysis of details of odds ratio, 95% CI, genetic models reported in total 11 (including present) meta-analysis published so far analyzing case--control studies of *MTHR* C677T polymorphism and breast cancer.

  SN     Author                No. of studies   Sample size   OR       95% confidence interval   Model   I^2^                          
  ------ --------------------- ---------------- ------------- -------- ------------------------- ------- ------------ ---------------- ------
  1      [@bb0635]             18               5467          7336     12,803                    1.03    0.97--1.08   T vs. C          34
  1.07   0.95--1.20            TT vs. CC        36                                                                                     
  1.06   0.95--1.19            TT vs. CT + CC   33                                                                                     
  1.02   0.95--1.10            TT + CT vs. CC   14                                                                                     
  2      [@bb0340]             22               8330          10,825   19,155                    1.01    0.95--1.08   CT vs. CC        NA
  0.99   0.86--1.15            TT vs. CC        NA                                                                                     
  3      [@bb0375]             18                                                                1.01    0.87--1.18   TT vs. CT + CC   NA
  1.04   0.97--1.11            TT + CT vs. CC   NA                                                                                     
  4      [@bb0435]             41               16,480        22,388   38,868                    1.04    1.00--1.07   T vs. C          NA
  1.13   1.01--1.25            TT vs. CC        NA                                                                                     
  1.03   0.99--1.07            TT + CT vs. CC   NA                                                                                     
  1.11   1.01--1.23            TT vs. CT + CC   NA                                                                                     
  5      [@bb0625]             37               15,260        20,411   35,671                    1.04    0.99--1.08   CT vs. CC        NA
  1.11   1.01--1.23            TT vs. CC        NA                                                                                     
  1.04   1.00--1.09            TT + CT vs. CC   NA                                                                                     
  1.09   0.99--1.20            TT vs. CT + CC   NA                                                                                     
  6      [@bb0600]             51               20,907        23,905   44,812                    0.93    0.88--0.98   T vs. C          NA
  0.96   0.92--1.01            CT vs. CC        NA                                                                                     
  0.87   0.78--0.95            TT vs. CC        NA                                                                                     
  0.89   0.82--0.97            TT vs. CT        NA                                                                                     
  0.88   0.80--0.96            TT + CT vs. CC   NA                                                                                     
  0.94   0.89--0.99            TT vs. CT + CC   NA                                                                                     
  7      [@bb0325]             13               3273          4419     7692                      1.12    1.02--1.23   T vs. C          NA
  1.35   1.10--1.67            TT vs. CC        NA                                                                                     
  1.37   1.11--1.70            TT vs. CT + CC   NA                                                                                     
  8      [@bb0320]             57               25,877        29,781   55,658                    0.94    0.89--0.98   T vs. C          NA
  0.98   0.96--1.00            CT vs. CC        NA                                                                                     
  0.98   0.96--0.99            TT vs. CC        NA                                                                                     
  0.98   0.96--1.00            TT vs. CT        NA                                                                                     
  0.95   0.92--0.99            TT + CT vs. CC   NA                                                                                     
  0.99   0.98--0.99            TT vs. CT + CC   NA                                                                                     
  9      [@bb0440]             36               8040          10,008   18,048                    1.23    1.13--1.37   T vs. C          77.3
  1.03   0.97--1.10            CT vs. CC        33.7                                                                                   
  1.38   1.16--1.63            TT vs. CC        58.2                                                                                   
  1.12   1.01--1.23            TT + CT vs. CC   51.5                                                                                   
  1.33   1.15--1.43            TT vs. CT + CC   50.3                                                                                   
  10     [@bb0500]             61               28,031        31,880   59,911                    0.97    0.93--1.00   TT + CT vs. CC   29.5
  1.05                         TT vs. CT + CC   29.5                                                                                   
  11     Present study, 2015   75               31,315        35,608   66,923                    1.08    1.03--1.13   T vs. C          63
  1.05   1.01--1.08            CT vs. CC        29                                                                                     
  1.17   1.06--1.28            TT vs. CC        60                                                                                     
  1.06   1.02--1.09            TT + CT vs. CC   48                                                                                     
  1.12   1.03--1.22            TT vs. CT + CC   55                                                                                     

NA = not given in paper.
